- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04200742
Standardized BAL Procedure for Critical Patients to Diagnose Pneumonia Pathogens (STABAL)
December 13, 2019 updated by: Wu Jianfeng
The Influences of Standardized Procedure of Bronchoalveolar Lavage on the Diagnosis of Pneumonia Pathogen of Critical Patients
In order to improve the accuracy of the diagnosis of pulmonary pathogens and reduce the adverse impact of excessive BAL volume on patients, this study intends to explore the most optimal lavage volume in the middle lobe and the lower lobe of critical patients as well as seeking for the best way to manage BALF samples by means of detecting alveolar proteins and bacterial composition in BALF samples.
The hypothesis is that the optimal lavage volume in the middle lobe and the lower lobe might be different.
And to sample BALF separately through sequential lavage might be a better way to improve the accuracy of the diagnosis of pneumonia pathogens.
Study Overview
Status
Unknown
Conditions
Detailed Description
This is a self-control study consisted of three parts.
Firstly, searching for the optimal lavage volume in the middle lobe and the lower lobe of critical patients by exploring the differences between the concentration of alveolar proteins among BALF samples of every participant.
Several BALF samples are seperately collected from every single participant through sequential lavage(an initial 20 ml saline lavage at main bronchus and 5 aliquots of 20 ml saline lavage at the subsegment of the right middle lobe or 6 aliquots of 20 ml saline lavage at the lower lobe) .
The concentration of Alveolar proteins including Surfactant protein B (SP-B), Surfactant protein D (SP-D) and Human typeⅠprotein (HTⅠ-56) will be determined by enzyme-linked immunosorbent assay (ELISA).
Meanwhile, the amount of living cells as well as the proportion of squamous cells and columnar cells in BALF samples will be counted.
Secondly, to confirm the optimal lavage volume through quantitative bacterial culture of BALF and sputum samples of participants.
And BALF samples will also be tested by next generation sequencing(NGS) to identify microorganism.
Thirdly, to observe the effect of BAL on respiratory and cardiovascular systems.
The Vital signs, arterial gas analysis, ventilator parameters and respiratory mechanical parameters of patients before and within 24 hours after the BAL procedure will be recorded.
Study Type
Observational
Enrollment (Anticipated)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jianfeng Wu, M.D
- Phone Number: 8454 020-87755766
- Email: wujianfeng9571@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Recruiting
- The First Affiliated Hospital, Sun Yat-sen University
-
Contact:
- Wu Jianfeng, M.D
- Phone Number: 8454 020-87755766
- Email: wujiafeng9571@163.com
-
Contact:
- Guan Xiangdong, M.D
- Phone Number: 8456 020-87755766
- Email: carlg@163.com
-
Principal Investigator:
- Wu Jianfeng, M.D
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
The study population is selected from the Departement of Critical Care Medicine of the First Affiliated Hospital of Sun Yat-sen University.
Description
Inclusion Criteria:
- Admitted to intensive care unit
- Mechanically ventilated patient
- 18 years old or above
Pneumonia diagnosed by one of 1 - 4 plus 5
- purulent endotracheal secretions or increasing oxygen requirements;
- body temperature exceeds 38.0 ℃;
- potentially pathogenic bacteria be isolated from the endotracheal secretions;
- leukocyte count exceeds 10×10^9 per liter or less than 4×10^9 per liter;
- new or persistent radiographic features of pneumonia without another obvious cause.
Exclusion Criteria:
- considered to be unsuitable for bronchoscopy by attending physician;
- underwent bronchoalveolar lavage within the last 48 hours;
- medical history of lobectomy
- airway bleeding or pulmonary edema
- refuse to sign the informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The optimal lavage volume at the middle lobe and the lower lobe, evaluated by the detection of SP-B, SP-D and HTⅠ-56 in bronchoalveolar lavage fluid (BALF).
Time Frame: 48 hours
|
For the reason that SP-B, SP-D and HTⅠ-56 only exists in terminal airway and alveolus, the concentrations of them in BALF indicates the abundance of terminal airway materials obtained by bronchoalveolar lavage.
SP-B, SP-D and HTⅠ-56 will be detected by enzyme-linked immunosorbent assay (ELISA).
|
48 hours
|
The best way to manage BALF samples, evaluated by comparing the bacterial diversity and abundance in separately collected BALF specimens and mixed BALF specimen.
Time Frame: 3 days
|
Mixed BALF specimen was a mixture of one tenth of separately collected BALF specimens.
The BALF specimens will be cultured at 37℃,5% carbon dioxide for 18 to 24 hours, using blood ager, chocolate ager and MacConkey ager.
Bacterial species will be identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) and the colony counts will be recorded.
Besides, BALF specimens will also be dectected by Next Generation Sequencing for the bacterial diversity and abundance.
As a reference, culture of the endotracheal aspiration will be conducted.
|
3 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of BALF samples, evaluated by counts of different kind of cells in BALF
Time Frame: 24 hours
|
The living cells of BALF will be counted by Trypan blue staining.
And the proportion of squamous cell and columnar cell will be counted by Wright-Giemsa staining.
|
24 hours
|
Recovery of bronchoalveolar lavage fluid
Time Frame: 1 hour
|
To record the volume of bronchoalveolar lavage fluid (BALF) recovered and calculate the recovery.
|
1 hour
|
Impact of bronchoalveolar lavage (BAL) on the cardiovascular system.
Time Frame: 30 minutes before BAL; 15 minutes, 1 hours, 3 hours, 9 hours, 19 hours and 24 hours after BAL
|
To observe the systolic arterial blood pressure (SAP), diastolic arterial blood pressure (DAP), mean arterial pressure (MAP) and heart rate (HR).
|
30 minutes before BAL; 15 minutes, 1 hours, 3 hours, 9 hours, 19 hours and 24 hours after BAL
|
Change of pulmonary static compliance (Cst).
Time Frame: 30 minutes before BAL; 15 minutes, 1 hours, 3 hours, 9 hours and 24 hours after BAL.
|
Cst will be measured with mechanical ventilator (Drager EvitaXL, Germany).
|
30 minutes before BAL; 15 minutes, 1 hours, 3 hours, 9 hours and 24 hours after BAL.
|
Chang of airway resistance (Raw).
Time Frame: 30 minutes before BAL; 15 minutes, 1 hours, 3 hours, 9 hours and 24 hours after BAL.
|
Raw will be measured with mechanical ventilator (Drager EvitaXL, Germany).
|
30 minutes before BAL; 15 minutes, 1 hours, 3 hours, 9 hours and 24 hours after BAL.
|
Change of PaO2/FiO2 ratio.
Time Frame: About 2 hours before BAL; 15 minutes, 3 hours, 9 hours, 19 hours and 24 hours after BAL.
|
PaO2 denotes the arterial oxygen partial pressure and FiO2 denotes the fraction of inspired oxygen.
|
About 2 hours before BAL; 15 minutes, 3 hours, 9 hours, 19 hours and 24 hours after BAL.
|
Change of arterial carbon dioxide partial pressure (PaCO2).
Time Frame: About 2 hours before BAL; 15 minutes, 3 hours, 9 hours, 19 hours and 24 hours after BAL.
|
PaCO2 will be measured by arterial blood gas analysis.
|
About 2 hours before BAL; 15 minutes, 3 hours, 9 hours, 19 hours and 24 hours after BAL.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Jianfeng Wu, M.D, First Affiliated Hospital, Sun Yat-Sen University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 16, 2019
Primary Completion (Anticipated)
May 1, 2020
Study Completion (Anticipated)
June 1, 2020
Study Registration Dates
First Submitted
December 6, 2019
First Submitted That Met QC Criteria
December 13, 2019
First Posted (Actual)
December 16, 2019
Study Record Updates
Last Update Posted (Actual)
December 16, 2019
Last Update Submitted That Met QC Criteria
December 13, 2019
Last Verified
December 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Standard BAL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia
-
King Edward Memorial HospitalCompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated PneumoniaIndia
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Venatorx Pharmaceuticals, Inc.Biomedical Advanced Research and Development AuthorityNot yet recruitingHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
Hannover Medical SchoolCharite University, Berlin, Germany; University of LeipzigUnknownCOVID-19 | Bacterial Pneumonia | Viral Pneumonia | Pneumonia Due to Streptococcus Pneumoniae | Pneumonia Due to H. Influenzae | Pneumonia, Organism Unspecified | Pneumonia in Diseases Classified Elsewhere | Pneumonia Due to Other Specified Infectious OrganismsGermany
-
Nantes University HospitalSociété Française d'Anesthésie et de RéanimationCompletedPneumonia | Sepsis | Ventilator-Associated Pneumonia | Hospital Acquired PneumoniaFrance
-
University Medical Centre LjubljanaUniversity of Ljubljana, Faculty of MedicineUnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired PneumoniaSlovenia
-
PfizerCompletedVentilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, United Kingdom, Vietnam, Philippines, China, Ukraine, Argentina, Brazil, Hungary, Romania, India, Japan, Taiwan, Latvia, Czechia, Slov... and more
-
Arpida AGTerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
ShionogiCompletedHospital Acquired Pneumonia (HAP) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)Israel, Spain, United States, Belgium, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Japan, Latvia, Philippines, Puerto Rico, Russian Federation, Serbia, Taiwan, Ukraine
-
Methodist Health SystemCompletedHospital-acquired Pneumonia | Ventilator-associated PneumoniaUnited States